Total trials
77
Active
7
Phase 3
16
Total enrollment
60,744
Pipeline matrix
Showing 14 of 14 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Empagliflozin/Metformin | — | — | — | — | — | 1 | |
| Metformin | — | — | — | — | — | 1 | |
| Empagliflozin/Linagliptin | — | — | — | — | — | 1 | |
| Ezetimibe 10 mg | — | — | — | — | — | 1 | |
| Anagliptin | — | — | — | 4 | |||
| Pitavastatin 4mg | — | — | — | — | 2 | ||
| KLH-2109+ Leurprorelin acetate Placebo | — | — | — | — | — | 1 | |
| KLH-2109 Placebo + Leurprorelin acetate | — | — | — | — | — | 1 | |
| JW0104+C2402 | — | — | — | — | — | 1 | |
| JW0104+C2403 | — | — | — | — | — | 1 | |
| C2402 | — | — | — | — | — | 1 | |
| JW2286 | — | — | — | — | — | 1 | |
| JW0061 SAD | — | — | — | — | — | 1 | |
| JW0061 MAD | — | — | — | — | — | 1 |
Next readouts
- 2025-11
- 2026-01-22
- 2026-04
- 2026-12-31
- 2027-03-31
- 2028-03-31
Top conditions
- Healthy18
- Hypercholesterolemia7
- Type 2 Diabetes Mellitus6
- Hypertension5
- Gout4
- Dyslipidemia4
- Benign Prostatic Hyperplasia3
- Acute Myocardial Infarction2
Frequently asked questions about JW Pharmaceutical
- How many clinical trials does JW Pharmaceutical have on ClinicalTrials.gov?
- JW Pharmaceutical is listed as the lead sponsor on 77 clinical trials in ClinicalTrials.gov, 7 of which are currently active (recruiting, enrolling, or ongoing).
- How many of JW Pharmaceutical's trials are in Phase 3?
- 16 of JW Pharmaceutical's trials are in Phase 3, spread across 14 active drug programs.
- What therapeutic areas does JW Pharmaceutical focus on?
- JW Pharmaceutical's most-studied conditions on ClinicalTrials.gov are Healthy, Hypercholesterolemia, Type 2 Diabetes Mellitus, Hypertension, Gout.
- When are JW Pharmaceutical's next clinical trial readouts?
- JW Pharmaceutical has 6 upcoming primary-completion readouts tracked here; the soonest is “To Evaluate the Safety/Tolerability and Pharmacokinetic Characteristics in Healthy Volunteers”, expected around 2025-11.